PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.
CME accredited course focussed on how new developments with antidiabetic drugs will impact the management of CVD. Member registration (free) is needed to enroll in this course
Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.
The UMC Utrecht's Center for Circulatory Health has developed algorithms with which the risk of CVD and the effect of medication to reduce this risk, can be predicted for every adult. Use of the risk calculators is free.
Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.
Prof. John Deanfield introduces a new way of thinking about CV risk management in patients and population, to reduce the burden of CVD in society.
This is a summary of the presentation by prof. John E Deanfield, in which he explains why diabetologists and cardiologists have to collaborate on the care of diabetes patients.
ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.
ESC 2018 The PURE cohort study and three other studies showed reduced risk of CV disease and mortality with higher healthy diet score in general populations worldwide.
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.
Trials on lowering Lp(a) have thusfar failed to show a CV outcome benefit. Brian Ference describes a more informative approach to look at Lp(a) data to identify who may benefit from Lp(a)-lowering therapy.
This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.